Biotechnology company Cartherics, which is developing immune cell therapies for the treatment of cancer, has entered a collaborative research agreement with TiCARos Co to assess its proprietary CLIP-CAR technology in Cartherics’ induced pluripotent stem cell (iPSC)-derived natural killer (NK) cells.
Privately-held Melbourne-based biotechnology company Cartherics, which is developing immune cell therapies for the treatment of cancer, has been granted US patent 11,400,145, entitled “Genetically modified cells and uses thereof”.
For most developers the security/performance trade off is still the hardest one to tackle, even as the cost of processing[…]
RISC has been overhyped. While it is an interesting low-level processor architecture, what the world needs is high-level system architectures,[…]
There are two flaws that are widespread in the industry here. The first is that any platform or language should[…]
Ajai Chowdhry, one of the founders and CEO of HCL is married to a cousin of a cousin of mine.[…]
I wonder when they will implement all of this, and what the pricing plans will be.FWIW, these days the proposed[…]